Sapropterin adherence among patients with phenylketonuria when using integrated versus nonintegrated specialty pharmacies

PURPOSE: To compare adherence rates, measured by the proportion of days covered (PDC), in patients with phenylketonuria (PKU) prescribed sapropterin utilizing an integrated health-system specialty pharmacy (HSSP) vs a nonintegrated specialty pharmacy. METHODS: This retrospective, observational study evaluated sapropterin fills between January and December 2024. Patient demographics, sapropterin prescription information, fill data, and phenylalanine (Phe) levels were collected. Data were analyzed by Wilcoxon rank-sum test or by χ2 analysis or Fisher's exact test, as appropriate. A logistic regression model predicting likelihood of adherence (PDC of ≥80%) used forward/backward elimination of covariates. RESULTS: Fifty-four patients were included (median age, 15 years; interquartile range [IQR], 9.25-28.5 years; 52% female), of whom 17 utilized the integrated HSSP and 37 used a nonintegrated specialty pharmacy. The median PDC was 0.97 (IQR, 0.95-0.99) for the HSSP group and 0.91 (IQR, 0.75-0.99) for the nonintegrated specialty pharmacy group, with a between-group difference of 0.07 (95% confidence interval [CI], -0.05 to 0.19; P = 0.23). However, achievement of high (≥90%) or threshold (≥80%) adherence was more likely in the HSSP group, with proportions of 88.2% vs 51.4% (P = 0.01) and 88.2% vs 67.6% (P = 0.18), respectively. The Phe concentration was numerically lower for the group with a PDC of ≥80% than for the group with a PDC of <80%, with mean (SD) levels of 8.6 (4.5) mg/dL and 11.0 (6.3) mg/dL, respectively (P = 0.32). Integrated HSSP use was associated with nearly 5-fold-greater odds of achieving threshold adherence (adjusted odds ratio, 4.98; 95% CI, 0.75-33.3; P = 0.096), although the difference was not statistically significant. CONCLUSION: Patients using the HSSP were more likely to achieve high adherence, although differences in overall median adherence rates were not statistically significant. These findings highlight the potential value of integrated pharmacy models and support further investigation into optimizing clinical outcomes.

Authors

Institutions

Publication Details

Journal
American Journal of Health-System Pharmacy
Published
2026-11-18
DOI
https://doi.org/10.1093/ajhp/zxag402
Primary Topic
Medication Adherence and Compliance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sapropterin adherence among patients with phenylketonuria when using integrated versus nonintegrated specialty pharmacies

Nicole M. Acquisto, Eran Tallis, Jessica T. Kozakiewicz, Calvin J. Meaney et al.
4 links
American Journal of Health-System Pharmacy
Medication Adherence and Compliance
article

Sapropterin adherence among patients with phenylketonuria when using integrated versus nonintegrated specialty pharmacies

Nicole M. Acquisto, Eran Tallis, Jessica T. Kozakiewicz, Calvin J. Meaney, Priya Duraisamy, Derek Rossetti, Mary B Riedy
article en

Abstract

PURPOSE: To compare adherence rates, measured by the proportion of days covered (PDC), in patients with phenylketonuria (PKU) prescribed sapropterin utilizing an integrated health-system specialty pharmacy (HSSP) vs a nonintegrated specialty pharmacy. METHODS: This retrospective, observational study evaluated sapropterin fills between January and December 2024. Patient demographics, sapropterin prescription information, fill data, and phenylalanine (Phe) levels were collected. Data were analyzed by Wilcoxon rank-sum test or by χ2 analysis or Fisher's exact test, as appropriate. A logistic regression model predicting likelihood of adherence (PDC of ≥80%) used forward/backward elimination of covariates. RESULTS: Fifty-four patients were included (median age, 15 years; interquartile range [IQR], 9.25-28.5 years; 52% female), of whom 17 utilized the integrated HSSP and 37 used a nonintegrated specialty pharmacy. The median PDC was 0.97 (IQR, 0.95-0.99) for the HSSP group and 0.91 (IQR, 0.75-0.99) for the nonintegrated specialty pharmacy group, with a between-group difference of 0.07 (95% confidence interval [CI], -0.05 to 0.19; P = 0.23). However, achievement of high (≥90%) or threshold (≥80%) adherence was more likely in the HSSP group, with proportions of 88.2% vs 51.4% (P = 0.01) and 88.2% vs 67.6% (P = 0.18), respectively. The Phe concentration was numerically lower for the group with a PDC of ≥80% than for the group with a PDC of <80%, with mean (SD) levels of 8.6 (4.5) mg/dL and 11.0 (6.3) mg/dL, respectively (P = 0.32). Integrated HSSP use was associated with nearly 5-fold-greater odds of achieving threshold adherence (adjusted odds ratio, 4.98; 95% CI, 0.75-33.3; P = 0.096), although the difference was not statistically significant. CONCLUSION: Patients using the HSSP were more likely to achieve high adherence, although differences in overall median adherence rates were not statistically significant. These findings highlight the potential value of integrated pharmacy models and support further investigation into optimizing clinical outcomes.

American Journal of Health-System Pharmacy
University of Rochester Medical Center (US), University of Rochester (US), University at Buffalo, State University of New York (US)
Good health and well-being
Medication Adherence and Compliance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon